Actinium Pharmaceuticals, Inc. announced that updated data from the recently complete Actimab-A and CLAG-M Phase 1 combination trial being conducted at the Medical College of Wisconsin (MCW) was presented at the 63rdAmerican Society of Hematology Annual Meeting and Exposition (ASH) that is being held December 11 – 14, 2021 in Atlanta, Georgia and virtually. This Phase 1 trial was a dose escalation study that evaluated Actimab-A, a CD33 targeting antibody radiation conjugate (ARC) armed with the alpha-emitting radioisotope Actinum-225, combined with CLAG-M (Cladribine, Cytarabine, G-CSF and Mitoxantrone), a salvage chemotherapy regimen for patients fit for intensive therapy. Actimab-A + CLAG-M Phase 1 Results: Complete remissions (CR/CRp) in all dose cohorts, 80% overall response rate (CR/CRp/MLFS) in patients receiving less than 4 lines of prior therapy with a total of 10 complete remissions across all four dose cohorts, 72% MRD negativity rate determined by flow cytometry compares favorably to 39% MRD negativity rate with CLAG-M alone in MCW's institutional experience. 60% response rate in patients receiving prior venetoclax therapy including 4 patients that achieved a complete remission. 75% of patients proceeded to a bone marrow transplant, excluding patients with prior transplant experience, Median time to best response was 40 days, No 30-day mortality, 0.75uCi/kg of Actimab-A identified as recommended Phase 2 dose.